scholarly journals Characteristics of graft‐ versus ‐host disease occurring after alemtuzumab‐containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival

2019 ◽  
Vol 188 (4) ◽  
pp. 550-559 ◽  
Author(s):  
Maria C. Finazzi ◽  
Cristina Boschini ◽  
Charles Craddock ◽  
Alessandro Rambaldi ◽  
Janice Ward ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Organ Involvement ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Transplants ◽  
Stem Cell Transplants

scholarly journals 316: Characteristics of chronic graft-versus-host disease in Brazilian recipients of allogeneic stem cell transplants

2007 ◽  
Vol 13 (2) ◽  
pp. 115
Author(s):  
L.F.S. Bouzas ◽  
M.C.P. Moreira ◽  
R.d.C.B. Tavares ◽  
D. Lerner ◽  
A.M. Azevedo ◽  
...  
Keyword(s):  
Stem Cell ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Cell Transplants ◽  
Stem Cell Transplants

scholarly journals Myasthenia Gravis Presenting as Graft versus Host Disease after Allogeneic Blood Stem Cell Transplant

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Zarir Ahmed ◽  
Martin Schoen ◽  
Nabeel Rajeh
Keyword(s):  
Stem Cell ◽  
Myasthenia Gravis ◽  
Graft Versus Host Disease ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Rare Manifestation ◽  
Cell Transplants ◽  
New Onset

Myasthenia gravis is a very rare manifestation of graft versus host disease after stem cell transplants. Herein, we describe a case of new-onset myasthenia gravis after a stem cell transplant 34 months ago in a patient with myelodysplastic syndrome.

Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5337-5337
Author(s):  
Sang Kyun Sohn ◽  
Dong Hwan Kim ◽  
Jin Ho Baek ◽  
Jong Gwang Kim ◽  
Kyu Bo Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Acute Gvhd ◽  
Clinical Parameters ◽  
Host Disease ◽  
Graft Versus Host ◽  
History Of

Abstract Background: As a series of our previous investigation (Haematologica, 2005. 90: 939–48) identifying poor prognostic factors (lymphocytopenia and visceral involvement) at the onset of acute GVHD (aGVHD) in patients with a history of aGVHD after allogeneic stem cell transplantation (SCT), we tried to identify variables that could predict the development of chronic GVHD of progressive or quiescent type (pq cGVHD) and patients’ outcome after the diagnosis of cGVHD in cohort of 99 patients who experienced aGVHD after allogeneic SCT. Patients and Methods: We evaluated the risk factors for cGVHD of pq cGVHD with various clinical parameters in patient group with a history of aGVHD and also the prognostic significance of various clinical parameters at diagnosis of cGVHD to determine the prognostic factor for GVHD-specific survival (GSS) in patients with pq cGVHD. Results: From 118 patient experienced aGVHD of any degree, 99 patients were evaluated for cGVHD. The cumulative incidence of overall and extensive pq cGVHD at 2 years was estimated as 84.4% and 63.1%, respectively. In univariate analyses for risk factors of pq cGVHD, severe grade 3,4 aGVHD, primary treatment failure (PTF), lymphocytopenia (≤100/μl), elevated ALP (>160IU/l), visceral involvement, hepatic or gut involvement were identified. Especially, severe aGVHD (p=0.022 and <0.001), PTF (p=0.009 and 0.010) for overall and extensive pq cGVHD, lymphocytopenia (p=0.031) for extensive pq cGVHD, and elevated ALP (p=0.001) for overall pq cGVHD were independent risk factors. The prediction model of subsequent pq cGVHD validated these risk factors with respect to the incidences of overall pq cGVHD (48.6% versus 91.9% for no risk factor versus 1~3 risk factor(s)) and of extensive pq cGVHD (34.2% versus 59.6% versus 92.2% for no / 1 / 2~3 risk factors). HLA-disparity and stem cell source did not influence on the development of pq cGVHD in this cohort. The GSS and probability of systemic immunosuppressive treatment at 2 year after diagnosis of cGVHD was estimated as 55.9% and 51.9%. The GSS was significantly associated with the performance status (p=0.004) and lymphocytopenia (≤ 1,000/μl, p=0.022) at diagnosis of cGVHD by Cox’s proportional hazard model. Conclusion: Severe aGVHD, PTF, lymphocytopenia and elevated ALP may be useful predictive factors for the development of pq cGVHD in a cohort of patients who experienced a GVHD after allogeneic SCT. Figure. The significance of the predictive model for the development of overall (A) or extensive chronic graft-versus-host disease (GVHD; B) after occurence of acute GVHD Figure. The significance of the predictive model for the development of overall (A) or extensive chronic graft-versus-host disease (GVHD; B) after occurence of acute GVHD

Sign in / Sign up

Export Citation Format

Share Document